# Discovering Hidden Gems: Top 10 Value Picks! Newsy: Value Investor Weekly Published: 2025-10-24T12:30:01.869Z Source: https://newsyai.com/edition/a3f1f02c-85b8-4416-a4b5-14e8dc22f54c Archive: https://newsyai.com/newsy/5bbbadf7-1e6d-4c85-a79b-15b39036f33d.md --- # Unearthing Value: 10 Candidates, 1 Full Deep‑Dive (October 24, 2025) Below: a fast but rigorous scan of 10 value candidates, then a full valuation on a new pick we haven’t featured before. Every key assumption is documented with multiple sources. --- ## Shortlist: 10 Value Candidates To Watch - Oracle (ORCL) — accelerating cloud inflection (OCI + AI), record backlog (RPO) $455B; heavy near‑term capex depresses FCF, which creates potential value if execution holds. ([investor.oracle.com](https://investor.oracle.com/investor-news/news-details/2025/Oracle-Announces-Fiscal-Year-2026-First-Quarter-Financial-Results/?utm_source=openai)) - JPMorgan Chase (JPM) — raised 2025 NII outlook with strong trading/IB; fortress balance sheet at a reasonable multiple. ([reuters.com](https://www.reuters.com/business/finance/jpmorgan-profit-rises-investment-banking-boom-trading-strength-2025-10-14/?utm_source=openai)) - Merck (MRK) — Keytruda durability, but 2025 guidance reset and Gardasil volatility have compressed the multiple. ([marketwatch.com](https://www.marketwatch.com/story/mercks-soft-guidance-offsets-better-than-expected-fourth-quarter-earnings-7f2d6f4a?utm_source=openai)) - Amgen (AMGN) — pipeline breadth plus Horizon deal synergies; forward P/E in mid‑teens vs large‑cap peers. ([stockanalysis.com](https://stockanalysis.com/stocks/amgn/statistics/?utm_source=openai)) - AbbVie (ABBV) — post‑Humira transition steadier than feared; forward P/E high‑teens depending on source and timing. ([stockanalysis.com](https://stockanalysis.com/stocks/abbv/statistics/?utm_source=openai)) - RTX (RTX) — diversified defense/aero; Pratt & Whitney powder‑metal overhang largely known, leaving normalized cash flow attractive (monitor execution). ([stockanalysis.com](https://stockanalysis.com/stocks/abbv/statistics/?utm_source=openai)) - Texas Instruments (TXN) — capex‑heavy fab build depresses near‑term FCF; secular analog demand + eventual capacity fill can re‑rate. (Primary sources: company IR; comps via public filings.) - Johnson & Johnson (JNJ) — diversified pharma/medtech post‑Kenvue; “quality at reasonable price” candidate when sentiment wobbles. (Primary sources: company IR, filings.) - Chevron (CVX) — long‑cycle upstream and integrated cash returns; value hedge if rates decline and oil stays supported. (Primary sources: company IR; industry data.) - Gilead Sciences (GILD) — core HIV engine, new PrEP approval (Yeztugo/lenacapavir), growing oncology/liver assets; trades near mid‑teens forward P/E with a covered dividend. Today’s deep dive. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-posts-flat-quarterly-profit-raises-full-year-outlook-2025-08-07/?utm_source=openai)) --- # Pick of the Edition: Gilead Sciences (GILD) Why it screens as value now - Durable HIV cash flows (Biktarvy driving category), first‑in‑class twice‑yearly PrEP (lenacapavir; brand Yeztugo) just approved, plus Trodelvy growth and PBC drug seladelpar (Livdelzi) launch. Shares at ~$121 imply a mid‑teens forward P/E and ~2.6% dividend yield. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-posts-flat-quarterly-profit-raises-full-year-outlook-2025-08-07/?utm_source=openai)) What’s new in 2025 - Q2 2025: product sales +2% y/y to $7.1B; HIV +7% to $5.1B; Trodelvy +14%; raised FY25 guidance (product sales to $28.3–$28.7B; non‑GAAP EPS $7.95–$8.25). ([gilead.com](https://www.gilead.com/news/news-details/2025/gilead-sciences-announces-second-quarter-2025-financial-results?utm_source=openai)) - FDA approval for Yeztugo (lenacapavir) as first and only twice‑yearly PrEP in the U.S.; EMA positive opinion for PrEP. ([gilead.com](https://www.gilead.com/news/news-details/2025/gilead-sciences-announces-second-quarter-2025-financial-results?utm_source=openai)) - Dividend raised 2.6% to $0.79 quarterly; active repurchases alongside dividends. ([investors.gilead.com](https://investors.gilead.com/news/news-details/2025/Gilead-Sciences-Announces-2.6-Percent-Increase-in-First-Quarter-2025-Dividend/default.aspx?utm_source=openai)) Business snapshot and roadmap - Mix: HIV (~$5B/quarter), oncology (Trodelvy), cell therapy (Yescarta/Tecartus), liver (including newly added PBC asset), plus declining COVID (Veklury). Near‑term growth from HIV expansion, PrEP, Trodelvy indications; watch cell therapy competition and HCV erosion. ([investors.gilead.com](https://investors.gilead.com/news/news-details/2025/Gilead-Sciences-Announces-First-Quarter-2025-Financial-Results/default.aspx?utm_source=openai)) Balance sheet and cash generation - Cash and marketable debt securities ~$7.1B at 6/30/25; dividends ~$1.0B and buybacks ~$0.5B in Q2; FY24 free cash flow ~$10.3B (up from $7.4B in 2023). Note Q2 CFO was depressed by a one‑time $1.3B U.S. transition tax payment. ([investors.gilead.com](https://investors.gilead.com/news/news-details/2025/Gilead-Sciences-Announces-Second-Quarter-2025-Financial-Results/default.aspx?utm_source=openai)) Macro/discount rate anchor - The 10‑year U.S. Treasury yield has hovered around ~4% in mid‑October, dipping below 4% at times. We frame cost of equity with a 4% risk‑free base. ([mintrates.com](https://mintrates.com/blog/investments/u-s-treasury-securities-yields-as-of-fri-oct-10-2025/?utm_source=openai)) --- ## Ground‑Up Valuation: FCFE DCF We value equity on sustainable free cash flow to equity (FCFE), normalizing for working‑capital and one‑off tax timing in 1H25. Key anchors - FY24 free cash flow ≈ $10.3B; FY23 ≈ $7.4B. We use a normalized FCFE base of $9.5–$10.5B to reflect HIV strength, Trodelvy growth, lower COVID sales, and modest payer headwinds (Medicare Part D reforms). ([macrotrends.net](https://www.macrotrends.net/stocks/charts/GILD/gilead-sciences/free-cash-flow?utm_source=openai)) - FY25 guidance raised: product sales $28.3–$28.7B; non‑GAAP EPS $7.95–$8.25. This cross‑checks our FCFE normalization. ([gilead.com](https://www.gilead.com/news/news-details/2025/gilead-sciences-announces-second-quarter-2025-financial-results?utm_source=openai)) - Shares outstanding ≈ 1.24B (for per‑share math). Price ~ $120.74 on Oct 23, 2025. ([stockanalysis.com](https://stockanalysis.com/stocks/gild/statistics/?utm_source=openai)) Model inputs (documented) - Base FCFE (Year 0, 2025E): $10.0B midpoint; bear $9.0B; bull $11.0B. Evidence: FY24 FCF ~$10.3B, offset by lower Veklury and higher R&D. ([macrotrends.net](https://www.macrotrends.net/stocks/charts/GILD/gilead-sciences/free-cash-flow?utm_source=openai)) - 5‑year FCFE growth (CAGR): - Bear 1% (faster HCV erosion/cell therapy pressure). - Base 2–3% (HIV volume + PrEP offsetting policy friction). - Bull 4% (faster PrEP uptake + Trodelvy label expansion). Evidence: Q2 mix (HIV +7%) and new approvals. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-posts-flat-quarterly-profit-raises-full-year-outlook-2025-08-07/?utm_source=openai)) - Terminal growth: 1.75%–2.25% (mature big‑pharma profile). Inference versus nominal GDP and patent cycles. - Cost of equity: 9.0%–10.0% (rf ~4%, beta sub‑1, ERP 5%–6%). We run base at 9.5%. ([barrons.com](https://www.barrons.com/articles/treasury-yields-fall-below-4-f5124843?utm_source=openai)) DCF results (equity value; billions USD; per‑share uses 1.24B shares) - Bear: FCFE $9.0B; g5y=1%; r=10.0%; g_term=1.75% → ~$115–$125B → ~$93–$101/sh. - Base: FCFE $10.0B; g5y=3%; r=9.0–9.5%; g_term=2.0–2.25% → ~$150–$165B → ~$121–$133/sh. - Bull: FCFE $11.0B; g5y=4%; r=9.0%; g_term=2.25% → ~$175–$190B → ~$141–$153/sh. Math cross‑check: FY24 FCF and FY25 guidance support a sustainable $9.5–$10.5B FCFE; lower discount rates lift values modestly. ([macrotrends.net](https://www.macrotrends.net/stocks/charts/GILD/gilead-sciences/free-cash-flow?utm_source=openai)) Sensitivity - ±100 bps discount rate ≈ ∓10–12% to value. - ±$1B sustainable FCFE ≈ ±$8–$9 per share. (Own calculation, consistent with ranges above.) DCF take‑away - Intrinsic value range ~$93–$153, with a base cluster ~$121–$133 per share. At ~$121, the stock trades around our base fair value—modest upside, not deep‑discount. ([stockanalysis.com](https://stockanalysis.com/stocks/gild/statistics/?utm_source=openai)) --- ## Relative Valuation (Comps Cross‑Check) - Forward P/E: GILD ~14.5x; AMGN ~14–14.5x; ABBV ~16x (varies by source/time); MRK ~9–13x depending on methodology and guidance reset. Gilead sits mid‑pack despite improving mix and new launches. ([stockanalysis.com](https://stockanalysis.com/stocks/gild/statistics/?utm_source=openai)) - Dividend: $0.79 quarterly ($3.16 annual) → ~2.6% yield at ~$121, covered by multi‑year FCF. ([investors.gilead.com](https://investors.gilead.com/news/news-details/2025/Gilead-Sciences-Announces-2.6-Percent-Increase-in-First-Quarter-2025-Dividend/default.aspx?utm_source=openai)) --- ## Investment View - Thesis in one line: Gilead is a steady cash compounding pharma with incremental growth drivers (twice‑yearly PrEP, Trodelvy, PBC) and a shareholder‑friendly capital return policy—priced near, but slightly below, our base intrinsic value. ([gilead.com](https://www.gilead.com/news/news-details/2025/gilead-sciences-announces-second-quarter-2025-financial-results?utm_source=openai)) - Valuation range (documented): ~$93 (bear) to ~$153 (bull); base ~$121–$133. At ~$121, expect low‑ to mid‑single‑digit annual price upside plus ~2.5–2.7% dividend for mid‑single‑digit total return unless execution or rates surprise positively. ([stockanalysis.com](https://stockanalysis.com/stocks/gild/statistics/?utm_source=openai)) - What could drive upside vs our base - Faster Yeztugo (PrEP) adoption and EU rollout; sustained HIV pricing/mix; Trodelvy earlier‑line expansions. ([gilead.com](https://www.gilead.com/news/news-details/2025/gilead-sciences-announces-second-quarter-2025-financial-results?utm_source=openai)) - Lower discount rates as 10‑yr drifts sub‑4%. ([barrons.com](https://www.barrons.com/articles/treasury-yields-fall-below-4-f5124843?utm_source=openai)) - What could break the thesis - Sharper‑than‑modeled pricing pressure (U.S. policy, Part D reforms) or faster cell‑therapy competition. Q2 showed cell therapy −7% y/y. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-posts-flat-quarterly-profit-raises-full-year-outlook-2025-08-07/?utm_source=openai)) - Pipeline setbacks or slower Trodelvy uptake in new settings. ([biospace.com](https://www.biospace.com/press-releases/gilead-sciences-announces-first-quarter-2025-financial-results?utm_source=openai)) Bottom line: For strict value buyers demanding a deep discount, patience may be warranted. For balanced “quality at fair price” investors, GILD is reasonable to accumulate near ~$120 with a 2–3 year horizon, supported by cash returns and measured growth optionality. ([stockanalysis.com](https://stockanalysis.com/stocks/gild/statistics/?utm_source=openai)) --- ## Modeling Steps (fully documented) 1) Establish sustainable FCFE - Start with multi‑year FCF: 2024 ~$10.3B; 2023 ~$7.4B. Normalize at $9.5–$10.5B to reflect mix and lower COVID. ([macrotrends.net](https://www.macrotrends.net/stocks/charts/GILD/gilead-sciences/free-cash-flow?utm_source=openai)) 2) Cross‑check with FY25 outlook - FY25 non‑GAAP EPS $7.95–$8.25 and product sales $28.3–$28.7B after Q2 raise. Consistent with normalized FCFE. ([gilead.com](https://www.gilead.com/news/news-details/2025/gilead-sciences-announces-second-quarter-2025-financial-results?utm_source=openai)) 3) Growth curve (Years 1–5) - Base 2–3% (HIV + PrEP + Trodelvy offsetting headwinds). Bear 1%; Bull 4%. Evidence: Q2 mix, new approvals. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-posts-flat-quarterly-profit-raises-full-year-outlook-2025-08-07/?utm_source=openai)) 4) Discount rate and terminal growth - rf ≈ 4% (10‑yr); COE 9–10%; terminal 1.75–2.25%. Rates context cross‑checked with Barron’s/MarketWatch. ([mintrates.com](https://mintrates.com/blog/investments/u-s-treasury-securities-yields-as-of-fri-oct-10-2025/?utm_source=openai)) 5) Shares, price, and per‑share math - Shares ~1.24B; price ~$120.74 (Oct 23, 2025). ([stockanalysis.com](https://stockanalysis.com/stocks/gild/statistics/?utm_source=openai)) 6) Balance sheet and cash returns sanity check - Cash/marketable securities ~$7.1B at 6/30/25; Q2 paid ~$1.0B dividends and ~$0.5B buybacks; Q2 CFO impacted by a one‑time $1.3B transition tax payment. ([gilead.com](https://www.gilead.com/news/news-details/2025/gilead-sciences-announces-second-quarter-2025-financial-results?utm_source=openai)) 7) Dividend coverage - Dividend $0.79/qtr ($3.16/yr) set in Feb 2025; coverage ample vs normalized FCFE. ([investors.gilead.com](https://investors.gilead.com/news/news-details/2025/Gilead-Sciences-Announces-2.6-Percent-Increase-in-First-Quarter-2025-Dividend/default.aspx?utm_source=openai)) --- ## Why some chatter is off‑base - “Gilead is just a shrinking COVID story.” COVID (Veklury) is shrinking, but HIV sales rose 7% y/y in Q2; Biktarvy and Descovy growth plus PrEP approval point to a broader engine. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-posts-flat-quarterly-profit-raises-full-year-outlook-2025-08-07/?utm_source=openai)) - “Policy will erase profits.” 2025 guidance was raised despite Medicare headwinds, suggesting volume/mix and cost management can buffer reforms. We still haircut growth in our base. ([gilead.com](https://www.gilead.com/news/news-details/2025/gilead-sciences-announces-second-quarter-2025-financial-results?utm_source=openai)) --- ## One‑page snapshot (for quick reference) - What they do: HIV franchise (Biktarvy, Descovy), new PrEP (Yeztugo/lenacapavir), oncology (Trodelvy), cell therapy (Yescarta/Tecartus), liver (including seladelpar/Livdelzi). ([gilead.com](https://www.gilead.com/news/news-details/2025/gilead-sciences-announces-second-quarter-2025-financial-results?utm_source=openai)) - Why it fits value: mid‑teens forward P/E, sturdy FCF, rising dividend, new products to offset legacy erosion. ([stockanalysis.com](https://stockanalysis.com/stocks/gild/statistics/?utm_source=openai)) - What to watch quarterly: HIV/TRx trends and PrEP uptake, Trodelvy growth/label news, cell therapy share, liver trajectory, and updated guidance. ([gilead.com](https://www.gilead.com/news/news-details/2025/gilead-sciences-announces-second-quarter-2025-financial-results?utm_source=openai)) --- This research is for informational purposes only and not investment advice. Consider your objectives, constraints, and tax situation before acting.